Form 4: Aethlon Medical Director Nicolas Gikakis Acquires Shares Through RSU Grant

Director Nicolas Gikakis reports acquisition of Aethlon Medical shares through a restricted stock unit (RSU) grant.

Summary

• Nicolas Gikakis, a director of Aethlon Medical Inc., reported a transaction on April 23, 2025.
• Gikakis acquired 142,857 shares of common stock through a grant of Restricted Stock Units (RSUs) at a price of $0.35.
• Following the transaction, Gikakis directly owns 174,320 shares of Aethlon Medical Inc.
• The RSUs vest in four equal quarterly installments starting June 30, 2025, and ending March 31, 2026, contingent upon continued service with the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of share acquisition by a director through an RSU grant, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather transparency.

Positives

• The acquisition of shares by a director signals confidence in the company's future.

Future Outlook

The vesting schedule of the RSUs indicates a commitment from the director to remain with the company until March 31, 2026.

Industry Context

This type of filing is standard for corporate insiders and provides transparency regarding their holdings in the company. It's common for companies, especially in the biotech sector, to use RSUs as part of their compensation packages to align management's interests with those of shareholders.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology industry, used by companies like Amgen, Gilead Sciences, and Regeneron to incentivize and retain key personnel.
• The vesting schedule of these RSUs, with quarterly installments over a year, is fairly standard compared to industry practices, which often include vesting periods ranging from one to four years.
• The size of the grant, 142,857 shares, would need to be assessed in relation to the company's overall share count and the director's total compensation package to determine if it is in line with industry benchmarks.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder confidence.

Key Dates

Keywords

Aethlon Medical, Director, Gikakis, RSU, Share Acquisition, Beneficial Ownership, AEMD